艾滋病治疗新药多替阿巴拉米片效果如何？

(Dolutegravir tablets) is a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. It is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a minimum weight of 40 kg). Among them, dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

In the Chinese mainland market, the launch of Suimeike (dolute abalamib tablets) has filled the gap in single-pill compound preparations of anti-AIDS drugs. China Business News reporter learned that Suimeike is the only three-in-one compound drug with dolutegravir (DTG) as the core. Patients only need to take Yui times a day, one tablet each time.

Professor Zhang Fujie, director of the Infection Clinical and Research Center of Beijing Ditan Hospital, said: " At present, global antiviral treatment is gradually entering the era of integrase inhibitors, and fixed-dose combination preparations have become a trend in future treatment. Integrase inhibitors have four main characteristics: stronger antiviral effects, smaller side effects, fewer drug interactions, and less resistance. As a single-pill combination drug containing the new generation integrase inhibitor DTG, the launch of Suimeike (dolute abalamib tablets) will bring a more convenient and efficient integrase inhibitor combination to Chinese HIV-infected patients, which is a major advancement in China's existing antiviral treatment."

At present, as far as Medical Companion Travel knows, the Indian company Emcurus produces (Abalamid Tablets, InBEC), a box of 30 tablets, priced at about RMB 1,000, please contact Medical Companion Travel for details.